July 15, 2008

Cytheris Wins E1.5 Million OSEO Grant for HCV Program

Cytheris has announced that OSEO, France's national agency for industrial innovation, has awarded the company with a no interest loan of E1.5 million to support its ongoing clinical development program in hepatitis C.

The OSEO award will provide partial funding for the hepatitis C virus (HCV) clinical development program of the company's lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth factor for immune T-cell recovery and enhancement.

Clinical trials conducted on more than 75 patients in Europe, the US and Canada have demonstrated the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells. Cytheris is currently conducting multiple international clinical studies of IL-7 in HCV, HIV and cancer.

Michel Morre, president and CEO of Cytheris, said: "This new OSEO support provided for our HCV study will partially cover the manufacturing, clinical studies and personnel costs associated with the program as well as its expansion to include additional clinical sites in Asia."